The aim was to examine anti-tumor necrosis factor α (anti-TNFα) therapy influence changes on Th17 and Th22 cells in patients with spondyloarthritis (SpA), and its correlation with changes in clinical and magnetic resonance imaging (MRI) activity and chronicity scores. The Th17 and Th22 cells were assessed at baseline, after 12 and 52 weeks of anti-TNFα therapy by flow cytometry (ClinicalTrials.gov NCT4682724). The percentages of both Th17 and Th22 cells were increased by 70% at baseline compared with healthy controls (both p < 0.01). During treatment, these two subsets increased further to be 170% (Th17) and 123% (Th22) above levels in healthy controls (both p < 0.01). The same subsets decrease their expression of IL-23R significantly during the observation period (p < 0.05). High levels of Th17 and Th22 cells at baseline were associated with the degree of chronic changes in the sacroiliac joints on MRI and a good clinical response to anti-TNFα treatment after one year. Plasma levels were not associated with clinical changes. Th17 cells, and Th22 subsets, increased during one year of anti-TNF-α therapy in SpA, regardless of their clinical improvement. This supports that both the Th17 and Th22 subsets could be involved in the progression in SpA.

中文翻译：

---

抗肿瘤坏死因子治疗可增加脊柱关节炎中的 Th17 和 Th22 T 辅助亚群。


目的是检查抗肿瘤坏死因子α（抗TNFα）治疗对脊柱关节炎（SpA）患者Th17和Th22细胞变化的影响，及其与临床和磁共振成像（MRI）活动和慢性评分变化的相关性。在抗 TNFα 治疗 12 周和 52 周后，通过流式细胞术（ClinicalTrials.gov NCT4682724）在基线时评估 Th17 和 Th22 细胞。与健康对照相比，Th17 和 Th22 细胞的百分比在基线时增加了 70%（均 p < 0.01）。在治疗期间，这两个子集进一步增加，比健康对照水平高出 170% (Th17) 和 123% (Th22)（均 p < 0.01）。在观察期间，相同亚群的 IL-23R 表达显着降低 (p < 0.05)。基线时高水平的 Th17 和 Th22 细胞与 MRI 上骶髂关节的慢性变化程度以及一年后抗 TNFα 治疗的良好临床反应相关。血浆水平与临床变化无关。 SpA 患者接受抗 TNF-α 治疗一年后，无论临床改善如何，Th17 细胞和 Th22 细胞亚群均有所增加。这支持 Th17 和 Th22 亚群都可能参与 SpA 的进展。